Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed fallopian tube cancer, Muellerian mixed tumor, endometrial cancer, uterine sarcoma, ovarian cancer with sarcoma parts, or cervical cancer
• * No ovarian epithelial cancer
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2 OR
• Karnofsky 70-100%
• Life expectancy:
• At least 3 months
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• Hemoglobin greater than 10.0 g/dL
• Hepatic:
• Bilirubin no greater than 1.25 times upper limit of normal
• Renal:
• Glomerular filtration rate at least 60 mL/min
• Cardiovascular:
• No atrial or ventricular arrhythmias
• No congestive heart failure even if stabilized on medication
• No New York Heart Association class III or IV heart disease
• No myocardial infarction within the past 6 months
• Other:
• No pre-existing sensory or motor neuropathy grade 2 or greater
• No active infection
• No other serious medical condition that would preclude study
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior immunotherapy
• Chemotherapy:
• No more than 1 prior chemotherapy regimen for the malignancy
• No other concurrent chemotherapy
• Endocrine therapy:
• Prior hormonal therapy within the past 10 days allowed
• No concurrent hormonal therapy
• Radiotherapy:
• At least 6 weeks since prior radiotherapy to no more than 25% of bone marrow
• Surgery:
• Not specified
• Other:
• At least 30 days since prior experimental agents
• No other concurrent therapies that would preclude study
• No concurrent participation in another study